Here are the 424B prospectus supplements from Kairos Pharma, Ltd. (KAPA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow KAPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KAPA filings page.
Kairos Pharma, Ltd. is registering 6,425,000 shares of common stock for resale pursuant to a prospectus supplement dated April 1, 2026. The registration covers 2,500,000 shares underlying pre-funded warrants (exercise price $0.001), 3,750,000 shares underlying common warrants (exercise price $1.40), and 175,000 shares underlying placement-agent warrants (exercise price $1.40).
This supplement attaches the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed March 31, 2026) and updates the Prior Prospectus dated February 4, 2025. Shares underlying the warrants were issued in a private placement that closed January 16, 2025. Shares outstanding were 21,411,198 as of March 31, 2026.
Kairos Pharma, Ltd. files a prospectus supplement to update its Form S-1 registration covering up to 16,680,100 shares of common stock, reflecting (i) resale of up to $15,000,000 (approximately 15,625,000) shares issuable under an equity line of credit with Helena Global Investment Opportunities I Ltd. and (ii) 1,055,100 shares held by Helena.
The supplement attaches the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and incorporates the 10-K disclosures by reference; the prospectus remains qualified by the previously filed Prospectus dated April 25, 2025.